Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets

22 Nov 2022 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta Tablets, 1 mg and 5 mg. Glenmark had received tentative approval by the United States Food & Drug Administration (USFDA) fortheir generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020.  

According to IQVIATM sales data for the 12?month period ending September 2022, the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately $644.5 million. 

Glenmark’s current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. 

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1990.65 -9.95 (-0.50%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×